Consistent with the results published from most of the trials on diabetic patients, our analysis also showed the cardiovascular efficacy of GLP‐1 RAs in the subgroup of patients with type 2 diabetes. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.